This article is one of six invited review articles published in the Missing the Mark: Hepatic Encephalopathy supplement, which includes CME-accredited articles published in Clinical Gastroenterology and Hepatology (CGH) and the Journal of Hospital Medicine (JHM). The program is administered by AGA in collaboration with the Society of Hospital Medicine. Each article will provide an expert perspective on a topic related to practice gaps in the care and management of patients with cirrhosis and hepatic encephalopathy. This program is commercially supported by Salix.
Faculty
Jeremy Louissaint, MD
Center for Liver Disease and Transplantation, Columbia University
Sasha Deutsch-Link, MD
Division of Gastroenterology and Hepatology, University of North Carolina
Elliot B. Tapper, MD
Division of Gastroenterology and Hepatology, University of Michigan
Learning Objectives
- Upon completion of reading this article, successful learners will be able to classify hepatic encephalopathy, identify conditions that modify the risk of hepatic encephalopathy, and summarize the public health burden of hepatic encephalopathy.
Released: June 11, 2022
Expires: May 31, 2026
Disclosures
Elliot B. Tapper, journal author, has served as a consultant to Norvartis, Axcella, andAllergan, has served on advisory boards for Mallinckrodt, Bausch Health, Kaleido, NovoNordisk, and has received unrestricted research grants from Gilead and Valeant. No other authorhas a conflict of interest.
Funding: Elliot B. Tapper receives funding from the National Institutes of Health through
NIDDK (1K23DK117055).
Jeremy Louissaint, journal author, is a recipient of the American Association for theStudy of Liver Diseases Advanced Hepatology Award 2021.
Sasha Deutsch-Link, journal author, was supported in part by NIH grant T32DK007634.
All relevant financial disclosures have been mitigated
Accreditation and designation statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
CME expiration date: May 31, 2026
